RALEIGH, N.C., Sept. 4 /PRNewswire/ -- MedThink Communications, an innovator in health care communications and public relations, has been retained by NanoBio Corporation to promote its novel technology that uses nano-sized particles to eradicate skin infections, without harming normal tissue.
MedThink will implement a scientifically based communications program that includes public relations, advocacy development and medical communications in order to advance NanoBio's lead products, two topical agents (NB-001 and NB-002) that safely treat cold sores and toenail fungus.
"The depth of our scientific expertise allows us to transform highly technical information into readily understandable messages that resonate with a company's key audiences," said Scott Goudy, partner at MedThink. "Our scientific staff works in tandem with the promotional and public relations teams to build a comprehensive, integrated communications program."
NanoBio's scientific platform is in various stages of testing for skin infections, shingles, eye infections, vaginitis, genital herpes, and mucosal vaccines against influenza and hepatitis B. The mucosal vaccines, delivered nasally, will carry antigens that serve to alert and rouse the immune system into action against each respective infection. In the future, NanoBio plans to apply its technology to other mucosal vaccines that may include tuberculosis, small pox, anthrax and other viral and bacterial diseases.
ABOUT MEDTHINK COMMUNICATIONS
MedThink Communications is an award-winning, full-service medical
agency whose communication services capture the essence of your brand and
transform it into compelling messages that inspire your target audiences.
Our innovative approach to advertising, medical communications, public
relations, media planning and placement, sales training and marketing
consulting serves as the perfect complement to strengthen our health care
partners' competitive edge.
|SOURCE MedThink Communications|
Copyright©2007 PR Newswire.
All rights reserved